E/M Coding Alert - 2003 Issue 6
DRUG PRICING: CMS Seeks Alternative To Inherent Reasonableness For Drugs
Subscribe or sign in to view the full article.
Article Overview
This article discusses CMS’s ongoing review of Medicare drug payment policy and its search for an alternative administrative approach amid concerns about average wholesale price-based pricing. It also places the issue in the context of congressional inaction, House committee attention, and state-level litigation affecting drug pricing data and reimbursement. The article is relevant to healthcare billing, Medicare payment policy, and organizations monitoring drug pricing oversight and reform.
Why This Topic Matters
Drug pricing methodology affects Medicare and Medicaid reimbursement and can influence payer liability, compliance attention, and market reporting practices. Readers tracking federal payment policy, legislative activity, and state enforcement actions can use this article to understand the broader policy environment around drug cost reporting.
What You Will Learn
- How CMS is responding to concerns about Medicare drug pricing methodology
- What broader federal and state pressures are influencing drug payment policy
- Why drug price reporting and reimbursement remain under scrutiny
- How congressional inaction affects administrative policy discussions
Who Should Read This
- Medical coders
- Billing professionals
- Revenue cycle staff
- Healthcare compliance professionals
- Payer policy analysts
- Practice administrators
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com